Pfizer ships its rival to Neupogen in US

Pfizer has introduced the firm’s Nivestym (filgrastim-aafi) biosimilar in the US, at the previously-promised “significant discount” to the current wholesale acquisition cost (WAC) of Amgen’s Neupogen original, and a double-digit reduction on the price of competing biosimilar and follow-on products.